200
Participants
Start Date
September 19, 2018
Primary Completion Date
November 30, 2026
Study Completion Date
September 30, 2027
Tislelizumab (BGB-A317)
Anti-PD-1 Antibody
COMPLETED
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
COMPLETED
The Affiliated Hospital of Military Medical Sciences, Beijing
RECRUITING
Beijing Cancer Hospital, Beijing
COMPLETED
The General Hospital of Shenyang Military, Shenyang
RECRUITING
Jilin Cancer Hospital, Changchun
RECRUITING
Harbin Medical University Cancer Hospital, Harbin
COMPLETED
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
Affiliated Zhongshan Hospital of Fudan University, Shanghai
COMPLETED
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School, Nanjing
COMPLETED
Jiangsu Province Hospital, Nanjing
RECRUITING
Anhui Provincial Hospital, Hefei
RECRUITING
Yidu Central Hospital of Weifang, Weifang
COMPLETED
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
COMPLETED
Zhejiang University College of Medicine Second Affiliated Hospital, Hangzhou
COMPLETED
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Fujian Medical University Union Hospital, Fuzhou
RECRUITING
Chongqing Cancer Hospital, Chongqing
COMPLETED
Hunan Cancer Hospital, Changsha
COMPLETED
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan
COMPLETED
Hubei Cancer Hospital, Wuhan
RECRUITING
Henan Cancer Hospital, Zhengzhou
COMPLETED
Guangdong Provincial Peoples Hospital, Guangzhou
COMPLETED
Nanfang Hospital of Southern Medical University, Guangzhou
COMPLETED
The Sixth Affiliated Hospital, Sun Yat Sen University, Guangzhou
RECRUITING
Meizhou People Hospital, Meizhou
RECRUITING
Huizhou First Hospital, Huizhou
RECRUITING
The Peoples Hospital of Hechi, Hechi
RECRUITING
The First Peoples Hospital of Yibin, Yibin
RECRUITING
Affiliated Hospital of Hebei University, Baoding
Lead Sponsor
BeiGene
INDUSTRY